Phase II pilot study of FOLFOXIRI plus panitumumab in metastatic RAS wild-type left-sided colorectal cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Ras Wild-type, Left Sided Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed diagnosis of advanced adenocarcinoma of the colon or rectum (colorectal cancer). 2) No previous systemic chemotherapy for metastatic disease -Subjects who have had prior adjuvant chemotherapy for non-metastatic disease are eligible if more than six months have elapsed after completing therapy. 3) RAS wild-type; left-sided tumor 4) ECOG performance status of 0-1.

You may not be eligible for this study if the following are true:

  • 1) Subjects with > grade 1 neuropathy. 2) Any active or uncontrolled infection. 3) Clinically significant cardiovascular disease within the past 6 months. 4) Major surgical procedure within 28 days prior to the start of study treatment.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.